Glenmark Pharmaceuticals Inc., USA, has announced a strategic move to manage the end-to-end commercialisation and distribution of RYALTRIS® (Olopatadine Hydrochloride and Mometasone Furoate) Nasal Spray in the United States, starting from April 1, 2026. This initiative marks a significant step in Glenmark’s efforts to establish a robust direct commercial presence in the US market.
RYALTRIS®, which was launched in the US in 2022, is approved by the U.S. Food and Drug Administration (FDA) for treating symptoms associated with Seasonal Allergic Rhinitis in adults and children aged 12 and above. The nasal spray combines an antihistamine and a corticosteroid, offering a convenient treatment option for patients.
The decision to directly handle the brand strategy, market access, and customer engagement for RYALTRIS® in the US allows Glenmark to better align with healthcare providers and respond to market demands. Marc Kikuchi, President & Business Head, North America, highlighted that this move is crucial for the company’s growth and its ability to support healthcare providers and patients nationwide.
RYALTRIS® has received approval in several key markets, including the European Union, the United Kingdom, Australia, South Korea, Russia, and China. In the fiscal year 2026, the product was launched in 11 additional markets, expanding its reach to 55 countries globally.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).